Compare MUX & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MUX | NVAX |
|---|---|---|
| Founded | 1979 | 1987 |
| Country | Canada | United States |
| Employees | 1432 | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | N/A | 1996 |
| Metric | MUX | NVAX |
|---|---|---|
| Price | $19.45 | $9.34 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 9 |
| Target Price | ★ $26.63 | $11.33 |
| AVG Volume (30 Days) | 1.0M | ★ 4.4M |
| Earning Date | 03-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 309.76 |
| EPS | N/A | ★ 2.58 |
| Revenue | N/A | ★ $1,123,479,000.00 |
| Revenue This Year | $22.52 | N/A |
| Revenue Next Year | $26.24 | N/A |
| P/E Ratio | ★ N/A | $3.62 |
| Revenue Growth | N/A | ★ 64.69 |
| 52 Week Low | $6.38 | $5.01 |
| 52 Week High | $29.70 | $11.85 |
| Indicator | MUX | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 34.24 | 45.42 |
| Support Level | $17.70 | $9.14 |
| Resistance Level | $20.59 | $10.42 |
| Average True Range (ATR) | 1.31 | 0.54 |
| MACD | -0.62 | -0.18 |
| Stochastic Oscillator | 15.48 | 4.92 |
McEwen Inc, formerly McEwen Mining Inc is a mining and minerals production and exploration company that focuses on precious and base minerals in Argentina, Mexico, and the United States. The company generates its revenue from gold and silver production. It owns and operates the wholly-owned El Gallo 1 mine in Mexico and holds a minority stake in the company that manages the San Jose mine in Argentina. More than half of the company's gold output comes from the El Gallo 1 mine, while the remaining gold production and the majority of silver production are sourced from the San Jose mine. Geographically, majority of production occurs in the United States.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.